About Blirt
Blirt is a Healthcare company based in Gdansk (Poland) founded in 2008 by Marian Popinigis, and was acquired by Qiagen in May 2022. Specialty enzymes for nucleic acid purification and sequencing are produced. Its chief executive, as recorded, is Piotr Lassota. Blirt offers products and services including Proteinase K and RNase Inhibitor. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Kits and Reagents. Its legal entity is BLIRT S.A.
Company details
BLIRT was established in 2008 in Gdansk, Poland, within the biotechnology sector. Specialty enzymes used in nucleic acid purification and sequencing are manufactured by the company. Molecular biology kits are supplied alongside these products. Protein production services are offered, encompassing the design of expression systems for commercial applications. Operations remain focused on enzyme and kit development in Europe.
Products & Services of Blirt
Blirt offers a comprehensive portfolio of products and services, including Proteinase K and RNase Inhibitor.
High-demand enzyme for protein digestion in molecular biology assays
Protects RNA from degradation during biological research applications
Investors in Blirt
Blirt has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Qiagen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Products and reagents for molecular diagnostic assays are supplied. | 1984 | qiagen.com | Hilden, Germany |
Investor details for Blirt
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Blirt
2 people are tracked at Blirt (2 in leadership).
| Name | Role | Group |
|---|---|---|
Marian Popinigis | Founder & Board Member | Leadership |
Piotr Lassota | CEO & President | Leadership |
Complete people profiles for Blirt
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Blirt
2 dated milestones of Blirt across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Blirt is founded.
- Exit Acquired by Qiagen.
Web traffic of Blirt
The website of Blirt (blirt.eu) receives about 4.7K visits a month and ranks #5,112,363 among all websites worldwide, #5,869 in Biotechnology and Pharmaceuticals.
- Monthly visits4.7K
▲ 22.6% vs previous month
- Unique visitors1.8K
per month
- Global rank#5,112,363
among all websites
- Category rank#5,869
Health · Biotechnology and Pharmaceuticals
- Bounce rate34%
- Pages per visit1.3
- Average visit2 sec
- DevicesDesktop 12% Β· Mobile 88%
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Blirt
Complete news archive for Blirt
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Blirt
Blirt was founded in 2008.
Blirt is headquartered in Gdansk, Poland. It is registered at Gdansk, Pomeranian Voivodeship, Poland.
Piotr Lassota is the CEO of Blirt, as recorded in our data.
BLIRT was established in 2008 in Gdansk, Poland, within the biotechnology sector. Specialty enzymes used in nucleic acid purification and sequencing are manufactured by the company. Molecular biology kits are supplied alongside these products. Protein production services are offered, encompassing the design of expression systems for commercial applications. Operations remain focused on enzyme and kit development in Europe.
Blirt offers Proteinase K and RNase Inhibitor.
Blirt has 1 investor. Key investors include Qiagen.
Blirt operates through Blirt S.A..
Yes. Blirt was acquired by Qiagen in May 2022.

